Singapore, Feb. 26 -- US-basedSunflower Therapeuticshas announced its first distribution agreement withPharmNXT Biotech, an Indian bioprocessing company. Through this agreement, Sunflower will commercially launch itsDaisy Petal Perfusion Bioreactor Systemin Asia, a significant step in the company's ongoing product commercialization.
Sunflower's innovative Daisy Petal perfusion fermentation system uses a single-use assembly designed specifically for intuitive installation and a simple user experience. The system's hardware and controls are engineered and optimised for in-vessel perfusion utilising a custom disposable stirred tank reactor outfitted with a unique in-vessel perfusion device that enables greater volumetric productivity from t...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.